stockportfolio.pro
Kamada Ltd. (KMDA)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Kamada Ltd. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $129.34M | $142.52M | $160.95M | $180.46M |
| Gross profit | $46.70M | $55.49M | $69.97M | $76.41M |
| Net income | $-2.32M | $8.28M | $14.46M | $20.20M |
| Net margin | -1.8% | 5.8% | 9.0% | 11.2% |
Source: Kamada Ltd. SEC filings (10-K).
What growth is priced into KMDA stock?
At today's market cap of $423.21M, Kamada Ltd. is priced for free-cash-flow growth of about 11.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $15.64M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of Kamada Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KMDA in your portfolio →
Kamada Ltd. financial history by metric
About Kamada Ltd.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Kamada Ltd. — frequently asked questions
What is Kamada Ltd.'s revenue?
Kamada Ltd. (KMDA) reported revenue of $180.46M for fiscal year 2025, up 12.1% from the prior year, according to its SEC filings.
Is Kamada Ltd. profitable?
Yes. KMDA earned net income of $20.20M in fiscal 2025, a net margin of 11.2%.
What is KMDA's P/E ratio?
Kamada Ltd. trades at a price-to-earnings ratio of about 20.9 based on the latest data in our nightly-refreshed cache.
How fast is Kamada Ltd. growing?
KMDA's revenue grew at roughly 11.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Kamada Ltd. have?
As of fiscal year 2025, KMDA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kamada Ltd.'s gross margin?
KMDA's gross margin was 42.3% in fiscal 2025 — gross profit of $76.41M on revenue of $180.46M.
What is Kamada Ltd.'s market cap?
Kamada Ltd. (KMDA) has a market capitalization of about $423.21M, based on the latest data in our nightly-refreshed cache.
When does Kamada Ltd.'s fiscal year end?
KMDA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into KMDA stock?
At today's market cap of $423.21M, Kamada Ltd. is priced for free-cash-flow growth of about 11.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $15.64M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Kamada Ltd.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.